From "How To Buy A Stock?" to Technical Analysis Training, we provide Complete Training:
Learn The Ropes
Engage In Our Community
Become an Expert
What Our Clients Say
– Dave Lindahl | RE Mentor, IncWhat I am most impressed with is the cleverness, yet simplicity that Alan’s system is built upon. It is written for the average person, The Blue Collar Investor.
– John and Beronica R. | Allen, TXMy wife and I recently purchased both of your books. They are clearly written and the examples are easy to understand as we have learned a lot of new information.
– Danielle H | Valparaiso, INThe thing I like the most about Alan’s covered call plan is that if you do enough research on the stock at the outset, you can feel comfortable owning it even if it goes down.
– Steve SorensenI want to thank you also for the incredibly good lists and articles that you and your team are putting together. I have learned so much from reading your articles and studying the weekly lists that I am feeling far more confident that I can invest much more wisely.
Recent Blog Posts | Visit The Blog (Weekly Training Articles & Commentary)
Interpreting Exit Strategy Calculations Versus Final Calculations
Mastering option calculations is an essential skill needed to attain the very highest covered call writing returns. Although the Ellman Calculator will do most of the heavy lifting for us, understanding the reasons behind these calculations and when and how to apply them, will make us all more skilled investors. Recently a BCI member sent […]
Ask Alan #160 – Comparing Protective Puts and Position Unwinding as Strike Moves Deep In-The-Money
Alan answers a question posed by Doug, who asks: Alan, What are your thoughts on the following: Purchased 100 shares of ALXN (Alexion Pharmaceuticals) on 3/15 at $135.18 and sold the $135 call expiring on 4/18 at $5.11. The stock is trading at $140.42 on 4/5 and considering buying a $135 put for $1.05 to […]
Covered Call Writing with a Biotech Company: A Real-Life Example with Argenx (NASDAQ: ARGX)
Covered call writing (as well as put-selling) premiums are directly related to the implied volatility of the underlying stock or exchange-traded fund (ETF). Biotech stocks are particularly volatile due to the success (or lack thereof) of the pharmaceuticals they are developing. Highly volatile underlyings represent the good news of higher premiums and the bad news […]
